Descovy

Antiretroviral Therapy, HIV test negative, HIV Infections + 12 more
Treatment
2 FDA approvals
20 Active Studies for Descovy

What is Descovy

EmtricitabineThe Generic name of this drug
Treatment SummaryEmtricitabine is an antiviral medicine used to treat HIV infection in adults. It is also combined with tenofovir alafenamide for the prevention of HIV-1 infection in adolescents and adults at high risk. The drug works by blocking HIV reverse transcriptase, which stops HIV from turning its RNA into DNA. Approved by the FDA in 2003, Emtricitabine is a type of drug called a nucleoside reverse transcriptase inhibitor (NRTI).
Emtrivais the brand name
image of different drug pills on a surface
Descovy Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Emtriva
Emtricitabine
2003
131

Approved as Treatment by the FDA

Emtricitabine, also called Emtriva, is approved by the FDA for 2 uses including HIV and adults and pediatric patients weighing at least 17 kg .
HIV
Helps manage Human Immunodeficiency Virus Type 1 (HIV-1) Infection
adults and pediatric patients weighing at least 17 kg

Effectiveness

How Descovy Affects PatientsEmtricitabine stops the virus that causes HIV from making more copies of itself. It is taken once per day, making it a long-lasting drug. Those taking it should be aware of the risks of lactic acidosis and liver problems.
How Descovy works in the bodyEmtricitabine is a special compound that stops the HIV virus from replicating itself. This is accomplished by blocking the HIV reverse transcriptase enzyme from forming new DNA strands. Without new strands, the virus cannot make copies of itself and its spread is stopped. This lowers the amount of virus in the body and helps reduce symptoms.

When to interrupt dosage

The proposed dose of Descovy is contingent upon the diagnosed situation, including HIV (Human Immunodeficiency Virus), Human Immunodeficiency Virus Type 1 (HIV-1) and HIV Transmission. The quantity of dosage fluctuates as per the technique of delivery detailed in the table beneath.
Condition
Dosage
Administration
Antiretroviral Therapy
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
HIV test negative
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
HIV Infections
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
HIV Transmission
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
Anti-Retroviral Agents
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
HIV
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
adults and pediatric patients weighing at least 17 kg
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
not requiring CYP3A inhibitors
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
treatment failure
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
Obesity
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral
Sexual Behavior
200.0 mg, , 100.0 mg, 133.0 mg, 167.0 mg, 10.0 mg/mL, 120.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Solution, Solution - Oral

Warnings

Descovy Contraindications
Condition
Risk Level
Notes
HIV
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Emtricitabine may interact with Pulse Frequency
There are 20 known major drug interactions with Descovy.
Common Descovy Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Emtricitabine.
Procainamide
Major
The excretion of Procainamide can be decreased when combined with Emtricitabine.
Topotecan
Major
The excretion of Topotecan can be decreased when combined with Emtricitabine.
Cefradine
Minor
The excretion of Cefradine can be decreased when combined with Emtricitabine.
Estrone sulfate
Minor
The excretion of Estrone sulfate can be decreased when combined with Emtricitabine.
Descovy Toxicity & Overdose RiskThe toxic dose of emtricitabine is not known. If someone takes too much emtricitabine, they may experience liver damage and build up of lactic acid. Treatment for overdose includes supportive care and dialysis.
image of a doctor in a lab doing drug, clinical research

Descovy Novel Uses: Which Conditions Have a Clinical Trial Featuring Descovy?

172 active clinical trials are currently assessing the potential of Descovy to treat HIV, HIV (Human Immunodeficiency Virus) in both adults and children weighing a minimum of 17 kg.
Condition
Clinical Trials
Trial Phases
HIV
155 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1
Sexual Behavior
10 Actively Recruiting
Not Applicable, Phase 4
HIV Infections
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting
treatment failure
0 Actively Recruiting
adults and pediatric patients weighing at least 17 kg
0 Actively Recruiting
HIV Transmission
0 Actively Recruiting
Obesity
639 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3
Antiretroviral Therapy
0 Actively Recruiting
HIV
0 Actively Recruiting
Obesity
0 Actively Recruiting
not requiring CYP3A inhibitors
0 Actively Recruiting
HIV test negative
0 Actively Recruiting
HIV
40 Actively Recruiting
Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4
Obesity
0 Actively Recruiting

Descovy Reviews: What are patients saying about Descovy?

5Patient Review
12/8/2017
Descovy for HIV
I was really impressed with this medication. I experienced some weight gain and occasional headaches, but on the whole it was a great experience.
5Patient Review
9/22/2016
Descovy for HIV
I felt a bit nauseous in the morning.
5Patient Review
4/24/2017
Descovy for HIV
I really enjoy taking this medication because I don't experience any negative side effects like weight gain. Additionally, it keeps my levels stable which is great.
4.3Patient Review
10/29/2019
Descovy for HIV
I experienced some discomfort and nausea during the first couple weeks of taking this medication, but it has since evened out. I've also noticed a change in my skin color, which is an unexpected but not unwelcome side effect.
3.7Patient Review
8/6/2021
Descovy for HIV Infection Pre-Exposure Prophylaxis
I've been on this medication for nine days now. It's caused a bit of headaches and rapid heartbeat at times; however, I'm going to give it another week or two before making any decisions about discontinuing use.
3Patient Review
6/3/2021
Descovy for HIV
I found Truvada much better as it had no noticeable side effects and was easy to take. Descovy, on the other hand, made me dizzy and out of sorts (restless and slightly depressed mood). I'd rather put up with osteoporosis from Truvada than feel like this.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about descovy

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Descovy medication for?

"Descovy was approved by the FDA in 2016 to treat HIV-1 infection in adults and pediatric patients in combination with other antiretoviral drugs."

Answered by AI

What is the difference between Truvada and Descovy?

"Descovy contains a form of tenofovir called tenofovir alafenamide (TAF) while Truvada contains the original form of tenofovir as tenofovir disoproxil fumarate (TDF)."

Answered by AI

What type of drug is Descovy?

"Descovy is a medication used to treat HIV. It combines two antiretroviral drugs, emtricitabine and tenofovir alafenamide, in one pill that is taken once a day along with another antiretroviral drug. Descovy comes in two different forms."

Answered by AI

Who needs to take Descovy?

"The medication Descovy is approved by doctors to be used as a preventative measure against HIV infection for adults and adolescents* who weigh at least 35 kilograms (kg), or about 77 pounds (lb). This medication is to be used by people who are at risk for contracting HIV, but do not already have the virus. Before starting to take Descovy for this purpose, you will need to get tested for HIV by a doctor."

Answered by AI

Clinical Trials for Descovy

Image of Neighborhood Healthcare in Escondido, United States.

Cagrilintide + CagriSema for Childhood Obesity

8 - 18
All Sexes
Escondido, CA
This study will look at how well CagriSema and cagrilintide help children and adolescents with excess body weight lose weight. The study has 2 parts: main and extension study. In the main study, participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to adolescents and adults) or placebo (a placebo looks like the treatment being tested, but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants who get semaglutide in the main study will not take part in the extension study. If participants take part in the extension study, they will get either CagriSema or cagrilintide in this part of the study. Like all drugs, the study drugs may have side effects. The total time participants will be in the main study is about 1 year and 6 months. If participants take part in the extension study, the total time is about 4 years and 10 months.
Phase 3
Waitlist Available
Neighborhood Healthcare (+30 Sites)Clinical Transparency (dept. 2834)Novo Nordisk A/S
Have you considered Descovy clinical trials? We made a collection of clinical trials featuring Descovy, we think they might fit your search criteria.Go to Trials
Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT
The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.
Waitlist Available
Has No Placebo
UConn Health (+2 Sites)Linda S Pescatello, PhD
Have you considered Descovy clinical trials? We made a collection of clinical trials featuring Descovy, we think they might fit your search criteria.Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

Tirzepatide + Resistance Exercise for Obesity in ALL Survivors

18+
All Sexes
Memphis, TN
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. Primary Objective(s): • To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise (three sessions per week) in adult survivors of childhood ALL with obesity or overweight (BMI ≥27 kg/m2) with ≥1 weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). The effectiveness will be estimated as the proportion of evaluable participants who achieve at least 5% weight loss from baseline to week 28. The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable. Secondary Objective(s): * Estimate the proportion of participants who adhere to the 28-week combined intervention. Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint. The adherence to each component of the intervention will also be reported. * Estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention. The study will target a mean weight reduction of 10% and consider \<5% unacceptable.
Phase 2
Waitlist Available
St. Jude Children's Research HospitalStephanie B Dixon, MD, MPH
Have you considered Descovy clinical trials? We made a collection of clinical trials featuring Descovy, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security